Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib with enzalutamide in mCRPC
NCT03395197Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2017
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of talazoparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Pfizer. Started Dec 2017; status: active, not recruiting.
02
Drugs
talazoparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03395197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03395197.